Tackling an uphill challenge for cancer research | Diaceutics

Tackling an uphill challenge for cancer research

October 16th, 2017



Ewelina Golebiewska of Diaceutics, is swapping her lab coat for lycra in November 2017 as she takes on the uphill challenge of the Padres Pedal The Cause charity cycle race in San Diego, California.

Alongside colleague John McNamara, she’ll be joining Team Pfizer to ride 156 miles over two days in the stunning California landscape. The weekend event donates 100 per cent of the money raised to cancer research projects in San Diego and attracts riders from all corners of cancer care, from survivors, families, doctors and researchers to pharma companies and now, Diaceutics.

Ewelina says, “Cancer will unfortunately affect most of us, whether directly or indirectly. I’ll be riding for my parents, friends and family members who have had, or may have to face cancer one day.”

Ewelina is already a keen cyclist and has climbed hills in the Pyrenees and the Basque Country but the San Diego course will be a new challenge. “The furthest I’ve ridden up to now is 80 miles but to have an 88 mile ride on the Saturday and then get back in the saddle for a 66 mile ride the next day will be something completely new to me. And of course it will be a whole lot warmer than at home in the UK. Hopefully the sunshine will give me that extra push to the finish line.”

In her role as Associate Director at Diaceutics, Ewelina works on multiple targeted assets in diseases such as acute myeloid leukemia, lymphomas, lung and breast cancer so she is delighted to find a different, if more energetic way of contributing to projects that improve new biomarkers, develop targeted therapies and get more patients tested with companion diagnostics at the right time.

She says, “With the advent of precision medicine, immuno-oncology, gene editing and other wonderful advances, I believe we are on the last stretch to beating cancer. But we need to support the amazing scientists and clinicians who got us here to ensure every last patient will have a shot at finding the therapy that works for them in the future.”

To support Ewelina and Padres Pedal The Cause click here.

Webinars & Podcasts

July 5th, 2019
Liquid Biopsy in NSCLC
August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Publications

June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications